A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More
Two promising Australian research projects have been awarded almost $3 million in funding from The Leona M. and Harry B. Helmsley Charitable Trust, to be administered by JDRF Australia.
A T1DCRN funded clinical trial published in Diabetes Care has shown that a pump with the ability to suspend insulin delivery when blood glucose levels begin to fall can reduce hypoglycaemic episodes without deterioration in glycaemic control.
The integration of real-time continuous glucose monitoring systems and pump therapy has been an important milestone in the management of type 1 diabetes, and advances in the technology field offers the potential to further improve clinical outcomes.
We are pleased to announce the recipients of the Type 1 Diabetes Clinical Research Network’s (T1DCRN) Mentored Clinician Researcher Fellowship Award (MCRF) for 2017.
The T1DCRN is an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC). One of the key objectives of the CRN is to nurture the next generation of clinical research leaders and secure the future of type 1 diabetes (T1D) research in Australia.
The international AdDIT trial group have this month published results of a four year clinical trial in The New England Journal of Medicine, finding that ACE inhibitors and statins did not change the primary outcome – the albumin to creatinine ratio – compared to placebo in adolescents with type 1 diabetes (T1D). Read More
A recent study published in Diabetologia from the TrialNet group has found that the shape of the glucose curve during a glucose tolerance test predicted risk of type 1 diabetes (T1D) development. TrialNet is an international network of leading academic institutions, clinicians, scientists and healthcare teams dedicated to the prevention of T1D. Read More
A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).
After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.
A large multinational study including data from 52,721 participants have found international differences in prevalence of coeliac disease (CD) in those with T1D. Coeliac disease has a known association with T1D, and this study aimed to examine global differences in prevalence and management to improve understanding of the impact of both conditions.
TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.
TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.